CALI, a wearable physical therapy device for those with vertigo, pitched at the annual event. Photo via getcalibalance.com

For the sixth year, the University of Houston and Rice University have joined forces to give their student entrepreneurs a program to thrive in. RED Labs and OwlSpark, the two universities' accelerator programs, just concluded their seventh class with a presentation from the companies.

Over the past 12 weeks, these 16 startups and their teams of entrepreneurs have worked on their company, developing it, learning how to fundraise for it, and engaging with all sorts of other valuable resources and mentors through the program.

"With an emphasis on experimentation and rapid iteration, we teach disciplined startup strategies that help (students) have an eye for reducing risks and increasing odds," says Kerri Smith, managing director of OwlSpark.

This summer's cohort was hosted out of Station Houston this year, but the two universities have worked together since year two of each of their programs.

"We're very proud of our partnership, because in most other cities, two universities like this would probably be rivals, but we're interested in camaraderie and collaboration in this cohort because they are the future generation of entrepreneurs of Houston," says Kelly McCormick, director of RED Labs. "We really think that this sets an example of how working together produces better results than working against each other."

Adren

While the invention of the EpiPen and other compact anaphylaxis solutions have saved lives, the products are still too large to be constantly available to those who need it. Adren's co-founders created a collapsible autoinjector that can be work as a wristband.

"A functioning drug is only one piece of the puzzle," says Jacob, co-founder of Adren. (He didn't state his last name.) "Medication is only effective if it is accessible to the patient."

The company plans to continue on and patent their product with hopes to enter the marketplace by the next few years.

CookLab

Anyone can find a recipe for anything with the tap of a few keys and the click of of few buttons, but once you add in dietary restrictions, things get tricky. Not to mention the fact that so many healthy recipes aren't even that good for you.

The team at CookLab wants to eliminate this unregulated and confusing corner of the internet. CookLab's first product is a web tool that can determine whether or not a recipe is healthy by the user dropping in the URL. This product is in beta right now.

Down the road, CookLab wants to create a tool for users to be able to submit a recipe they want to make, then have CookLab generate a modified version that follows any dietary needs.

INSU

In a state of emergency where electricity is out, the diabetic population is forced to gamble with their lives when it comes to keeping their insulin insulated and cool.

INSU has a solution. The startup has created a battery operated cooler that can keep insulin from spoiling for 30 days. The battery can be charged by wall outlet or even solar panel.

The company plans to market directly to consumers as well as make strategic partnerships with emergency and health organizations.

auggie

Merchandise lines at concerts are quite possibly the single-most buzzkill of any show. In the age of UberEats and order-ahead apps, auggie sees a solution.

While you're at a show, you can easily order your favorite merch items on the app and choose to have it set aside for pickup that day or even get it mailed to you. The app is live on some downloading stores.

LilySpec

The speculum OB/GYNs use on their patients hasn't changed in 150 years, and, while effective, can be uncomfortable to patients during use. But this doesn't have to be the case.

LilySpec is a speculum designed with the patient in mind. The device is silently deployed, silicon coated for comfort, and adjustable for all women.

The LilySpec team will finish its clinical product this year, and the company's medical partners here in Texas will be able to use it on patients.

Myze

How do you staff a team for an unpredictable job? Emergency rooms face this challenge every single shift. Too many staffers makes the establishment bleed money, while too few causes burnout and even sacrifices quality of care.

Myze is developing a software platform that can use artificial intelligence and predictive analytics to help ERs better staff their teams.

CALI

Those suffering from Vertigo feel like the whole world has turned upside down. CALI is a device that helps those people turn it right back around.

The wearable device allows for users to do balance exercises and claim back control of their own situation.

DASH Innovations

For those relying on a catheter, changing it out requires 150 monthly procedures on average. Each one is another opportunity for infection.

DASH Innovations has created UrinControl, a urethral valve for pediatric patients that can be installed once a month and operated with a remote to control the bladder.

Get-A-Grip

Holding onto a cup is something most everyone takes for granted. For arthritis or muscle damage patients, it's a daunting daily task.

Get-A-Grip is designed to distribute the weight of the cup along the grip and make it easier and more comfortable to hold. While originally designed with these patients in mind, the grip comes in four sizes, with the smallest being perfect for babies grabbing at bottles or small children holding cups.

Everest Security

Preparing for and preventing phishing email-originated data breaches is the new normal for companies, but it's impossible to prevent employees from accidentally opening suspicious emails without thinking.

While there are plenty software protection companies out there, Everest Security couples their software solution with education, a core component for the company.

KickedOC

There are 2 million homes supposedly dedicated for off-campus housing for students, but no one-stop shop to find them. KickedOC is attempting to be that one-stop shop and make it easier for students to find their semester homes.

With listings already up in Houston, the startup hopes to expand its platform to College Station and other Texas college towns next.

Mismo Minds

Creating a creative team can be difficult if you don't have the connections already. Mismo Minds is a platform for artists, videographers, directors, etc. to join forces with others who share their creative vision. It's a social networking tool, project management platform, and job board all rolled into one.

Sports Betz

Typically for sports betting, you have two options: Impersonal bets with large pools or friendly wagers that might not ever pay off. Sports Betz is a platform where the competitive gamblers can casually bet with friends and family — but the money is pulled up front.

CIND

Chivalry is not dead, argues CIND, a new dating app. The app allows for potential matches to introduce themselves with a gift — which range from $2 to $100. Though, the recipient doesn't just walk away with the cash. The money actually goes to the recipient's nonprofit of choice. Only after the donation is made can matches start chatting.

CIND (pronounced like "Cindy") is basically digital donation dating, and everyone wins.

PCATCopycat

The Pharmacy College Admission Test isn't easy — and preparation isn't cheap.

PCATCopycat puts the power back into the hands of students. The online course is only $200 — way cheaper and easier for future pharmacists to navigate.

Second Act

Second Act is the startup that isn't. The non-company started the program with the idea of matching retirees with short-term work at various startups with the thought being that they have a lot of experience and a lot of time on their hands. While a great idea in theory, Second Act hit some walls and the company and idea are no more. The team, however, has a bright future in Houston innovation at other startups and companies.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

NASA unveils Artemis III astronauts at Johnson Space Center in Houston

To the moon

NASA on Tuesday, June 9, revealed the crew for its Artemis III mission, the next step in the space agency's plan to eventually land astronauts on the moon.

The announcement came two months after Artemis II's record-breaking trip around the moon that surpassed the distance record of Apollo 13.

NASA's Randy Bresnik, Frank Rubio, Andre Douglas and the European Space Agency's Luca Parmitano won't fly to the moon or land on the surface. Instead, they’ll orbit Earth while practicing docking their Orion capsule with two lunar landers.

“To the Artemis III crew, we wish you Godspeed on the journey ahead,” said NASA administrator Jared Isaacman.

Elon Musk’s SpaceX and Jeff Bezos’ Blue Origin are racing to deliver the lunar landers. The two-week demo is targeted for 2027. Blue Origin suffered a recent setback when its massive rocket exploded during an engine-firing test on the launch pad in Florida, shaking nearby homes and illuminating the sky with an orange fireball.

NASA's Jeremy Parsons said the setback is a learning opportunity and that the space agency is confident Blue Origin's rocket will be ready in time.

NASA's Artemis program aims to return astronauts to the moon's surface for the first time since the 1970s. A recent revamp of the program announced by Isaacman aims to fast-track it similarly to the Apollo era, adding the upcoming spaceflight around Earth before eyeing a lunar landing in 2028.

“We are certainly humbled as a crew to be able to be your crew that executes this Artemis III mission in space,” said Bresnik, Artemis III commander.

Added Douglas, mission specialist: “My brain — it is going a mile a minute right now. But my heart, it is so warm. It is so full."

In May, NASA awarded hundreds of millions of dollars in contracts to four companies, including Blue Origin, to build landers, rovers and drones for a future moon base. Isaacman said the goal of the moon base is to lay the foundation for a Mars expedition.

Meta to bring $115 million AI data center training initiative to Houston

ai workforce

Meta and Associated Builders and Contractors have entered into a partnership to invest $115 million in training programs for the construction of AI data centers, with a portion of the project launching in Houston.

The companies announced June 8 that they would open America’s Workforce Academies at ABC chapter training centers in Houston; Indianapolis; Baton Rouge, Louisiana; and Columbus, Ohio.

The academies will offer career readiness and safety training, plus five weeks of hands-on education. Participants who complete the program will be granted a job offer from contractors working on Meta projects.

“The AI revolution is bringing change but also historic opportunities,” Dina Powell McCormick, Meta president and vice-chairman, said in a news release. “Skilled workers electrified rural America one pole at a time. They manned the factories that built the arsenal that won World War II. Now a new generation will pour the foundations and lay the fiber that secures American strength in this new age.”

Overall, the Meta and ABC aim for the academies to build a more sustainable pipeline of skilled construction workers and ensure safety and job readiness for the surging number of data center projects underway.

“This new program is an innovative talent solution that is a critical part of addressing the construction industry’s ongoing workforce shortage and creates an accelerated, new-entrant strategy for job seekers ... The sustained demand for data center construction technicians means the industry needs an all-of-the-above approach to address this shortage and grow the construction talent pool,” Michael Bellaman, ABC president and CEO, added in the release.

In Texas, Meta, the parent company of Facebook and Instagram, has launched or broken ground on data centers in El Paso, Fort Worth and Temple. The company announced in March that it planned to grow its El Paso Data center by 1 gigawatt, representing more than a $10 billion investment.

Apart from Meta, Texas has attracted data center development to power other giants like Google and Amazon in recent years. In turn, Texas has been predicted to become the biggest data center market. Commercial real estate services provider JLL reported this spring that the state could topple Northern Virginia as the world’s largest data-center market by 2030. Similarly, CBRE predicted that Houston's data center capacity could double by 2028. Read more here.

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.